Private Management Group Inc. lowered its holdings in shares of OraSure Technologies, Inc. (NASDAQ:OSUR – Free Report) by 30.0% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 3,797,682 shares of the medical instruments supplier’s stock after selling 1,624,447 shares during the period. Private Management Group Inc. owned about 5.51% of OraSure Technologies worth $16,938,000 as of its most recent filing with the SEC.
A number of other large investors also recently added to or reduced their stakes in OSUR. Quadrature Capital Ltd bought a new stake in OraSure Technologies in the fourth quarter worth $28,000. Legal & General Group Plc bought a new position in shares of OraSure Technologies during the second quarter valued at about $30,000. Prudential Financial Inc. bought a new stake in OraSure Technologies in the second quarter valued at approximately $31,000. Diversify Wealth Management LLC bought a new stake in OraSure Technologies in the first quarter valued at approximately $36,000. Finally, Diversify Advisory Services LLC purchased a new stake in shares of OraSure Technologies during the second quarter valued at approximately $47,000. Hedge funds and other institutional investors own 93.50% of the company’s stock.
OraSure Technologies Price Performance
OSUR opened at $3.60 on Friday. OraSure Technologies, Inc. has a one year low of $2.08 and a one year high of $4.58. The business has a 50 day simple moving average of $4.05 and a two-hundred day simple moving average of $3.54. The firm has a market capitalization of $248.29 million, a price-to-earnings ratio of -5.22 and a beta of 1.00.
Analysts Set New Price Targets
Get Our Latest Research Report on OraSure Technologies
OraSure Technologies Profile
OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.
The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.
See Also
- Five stocks we like better than OraSure Technologies
- From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
- These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
- Venture Into High-Volatility Corners of the Market With These 3 ETFs
- 3 Retail Stocks to Watch After a Big Consumer Earnings Week
Want to see what other hedge funds are holding OSUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OraSure Technologies, Inc. (NASDAQ:OSUR – Free Report).
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
